Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Interest Expenses (2021 - 2025)

SAB Biotherapeutics' Interest Expenses history spans 5 years, with the latest figure at $63462.0 for Q4 2025.

  • For Q4 2025, Interest Expenses fell 10.46% year-over-year to $63462.0; the TTM value through Dec 2025 reached $240664.0, down 24.42%, while the annual FY2025 figure was $240664.0, 24.41% down from the prior year.
  • Interest Expenses reached $63462.0 in Q4 2025 per SABSW's latest filing, up from $43292.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $93119.0 in Q2 2024 to a low of $43292.0 in Q3 2025.
  • Average Interest Expenses over 5 years is $73519.6, with a median of $73228.0 recorded in 2021.
  • Peak YoY movement for Interest Expenses: soared 32.33% in 2022, then tumbled 44.52% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $66275.0 in 2021, then surged by 32.33% to $87699.0 in 2022, then fell by 11.2% to $77879.0 in 2023, then dropped by 8.99% to $70876.0 in 2024, then decreased by 10.46% to $63462.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Interest Expenses are $63462.0 (Q4 2025), $43292.0 (Q3 2025), and $64345.0 (Q2 2025).